Project Grant F32AI197578
Award Date 10/14/26
Completion Date 6/30/27
Dollars Obligated $160K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $713,383 on July 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms and dynamics of genome plasticity in antifungal-resistant Candida species. The project addresses the molecular drivers of antifungal resistance in Candida albicans, Candida glabrata, and Candida auris through examination of large DNA amplification events, aneuploid...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $225,628 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify genetic mechanisms of polyene resistance in Candida glabrata using saturating transposon mutagenesis coupled with next-generation DNA sequencing (TN-SEQ). The project will implement TN-SEQ to mutate and barcode every gene in C. glabrata and profile resistance to three approved...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, Baltimore $233,250 in project grant funding (R21AI199182) on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research to characterize the evolution of multidrug resistance in Candida auris, a newly emerged fungal pathogen associated with invasive candidiasis worldwide and mortality rates approaching 68 percent. The recipient will prospectively...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $412,324 on June 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate whether echinocandin susceptibility can be restored to cross-resistant Candida strains by targeting genes that antagonize FKS gene products. The research uses genome-wide transposon sequencing screens in two cross-resistant derivatives of Candida glabrata to identify candidate genes and...
- The National Institute of Allergy and Infectious Diseases awarded Texas A&M University System Health Science Center $192,500 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research into novel antifungal therapeutics. The award funds structure-based design, synthesis, and validation of small molecule inhibitors targeting fungal SEC14 phosphatidylinositol transfer proteins as a strategy to combat multi-drug-resistant fungal infections,...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded the Regents of the University of Michigan $194,400 on August 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant K99AI201933) to define the fungal and host determinants of Candida auris skin colonization. The research addresses mechanisms by which Candida auris, an emerging multidrug-resistant fungal pathogen classified by the...
- The National Institute of Allergy and Infectious Diseases awarded Regents of the University of Michigan $411,078 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify novel antifungal compounds from symbiotic bacteria capable of combating drug-resistant Candida auris. The research exploits symbiotic bacteria—organisms that co-exist with and benefit their eukaryotic hosts—as a source of antifungal molecules with low mammalian toxicity. The...
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee $230,313 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a genome-wide CRISPR screening platform in diploid Candida albicans for identifying mechanisms of antifungal resistance. The project will create tools for efficient DNA transformation and CRISPR-based genome editing in C. albicans, then apply these tools to perform genome-wide screening to...
- The National Institute of Allergy and Infectious Diseases awarded the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $449,625 on June 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study regulation of Candida albicans biofilm formation on central venous catheters. The project investigates how transcription factor networks control Candida albicans biofilm development under physiological bloodstream conditions. Candida albicans...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a $489,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, with completion targeted for July 31, 2027. This award funds biomedical research aimed at identifying and characterizing novel antifungal drug targets within Candida albicans cell wall stress response pathways. The research focuses on the Target...